Neurologic medications are medications used to treat various neurological disorders and disease symptoms.
The global Nervous System Chemicals market was valued at US$ 80020 million in 2023 and is anticipated to reach US$ 112840 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Nervous System Chemicals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nervous System Chemicals.
Report Scope
The Nervous System Chemicals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nervous System Chemicals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nervous System Chemicals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Ely Lilly
Actavis(Teva Pharmaceuticals)
Mylan(Viatris)
UCB
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan(AbbVie)
GSK
Otsuka Pharmaceutical
Takeda
Novartis
Johnson & Johnson
Eisai
Kelun Pharmaceutical
Humanwell Pharmaceutical
Enhua Pharmaceutical
Yangzijiang Pharmaceutical
Segment by Type
Non-prescription Drugs
Prescription
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nervous System Chemicals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nervous System Chemicals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Nervous System Chemicals Market Overview
1.1 Product Overview and Scope of Nervous System Chemicals
1.2 Nervous System Chemicals Segment by Type
1.2.1 Global Nervous System Chemicals Market Value Comparison by Type (2024-2030)
1.2.2 Non-prescription Drugs
1.2.3 Prescription
1.3 Nervous System Chemicals Segment by Application
1.3.1 Global Nervous System Chemicals Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Nervous System Chemicals Market Size Estimates and Forecasts
1.4.1 Global Nervous System Chemicals Revenue 2019-2030
1.4.2 Global Nervous System Chemicals Sales 2019-2030
1.4.3 Global Nervous System Chemicals Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Nervous System Chemicals Market Competition by Manufacturers
2.1 Global Nervous System Chemicals Sales Market Share by Manufacturers (2019-2024)
2.2 Global Nervous System Chemicals Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Nervous System Chemicals Average Price by Manufacturers (2019-2024)
2.4 Global Nervous System Chemicals Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nervous System Chemicals, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nervous System Chemicals, Product Type & Application
2.7 Nervous System Chemicals Market Competitive Situation and Trends
2.7.1 Nervous System Chemicals Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Nervous System Chemicals Players Market Share by Revenue
2.7.3 Global Nervous System Chemicals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Nervous System Chemicals Retrospective Market Scenario by Region
3.1 Global Nervous System Chemicals Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Nervous System Chemicals Global Nervous System Chemicals Sales by Region: 2019-2030
3.2.1 Global Nervous System Chemicals Sales by Region: 2019-2024
3.2.2 Global Nervous System Chemicals Sales by Region: 2025-2030
3.3 Global Nervous System Chemicals Global Nervous System Chemicals Revenue by Region: 2019-2030
3.3.1 Global Nervous System Chemicals Revenue by Region: 2019-2024
3.3.2 Global Nervous System Chemicals Revenue by Region: 2025-2030
3.4 North America Nervous System Chemicals Market Facts & Figures by Country
3.4.1 North America Nervous System Chemicals Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Nervous System Chemicals Sales by Country (2019-2030)
3.4.3 North America Nervous System Chemicals Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nervous System Chemicals Market Facts & Figures by Country
3.5.1 Europe Nervous System Chemicals Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Nervous System Chemicals Sales by Country (2019-2030)
3.5.3 Europe Nervous System Chemicals Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nervous System Chemicals Market Facts & Figures by Country
3.6.1 Asia Pacific Nervous System Chemicals Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Nervous System Chemicals Sales by Country (2019-2030)
3.6.3 Asia Pacific Nervous System Chemicals Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nervous System Chemicals Market Facts & Figures by Country
3.7.1 Latin America Nervous System Chemicals Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Nervous System Chemicals Sales by Country (2019-2030)
3.7.3 Latin America Nervous System Chemicals Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nervous System Chemicals Market Facts & Figures by Country
3.8.1 Middle East and Africa Nervous System Chemicals Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Nervous System Chemicals Sales by Country (2019-2030)
3.8.3 Middle East and Africa Nervous System Chemicals Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nervous System Chemicals Sales by Type (2019-2030)
4.1.1 Global Nervous System Chemicals Sales by Type (2019-2024)
4.1.2 Global Nervous System Chemicals Sales by Type (2025-2030)
4.1.3 Global Nervous System Chemicals Sales Market Share by Type (2019-2030)
4.2 Global Nervous System Chemicals Revenue by Type (2019-2030)
4.2.1 Global Nervous System Chemicals Revenue by Type (2019-2024)
4.2.2 Global Nervous System Chemicals Revenue by Type (2025-2030)
4.2.3 Global Nervous System Chemicals Revenue Market Share by Type (2019-2030)
4.3 Global Nervous System Chemicals Price by Type (2019-2030)
5 Segment by Application
5.1 Global Nervous System Chemicals Sales by Application (2019-2030)
5.1.1 Global Nervous System Chemicals Sales by Application (2019-2024)
5.1.2 Global Nervous System Chemicals Sales by Application (2025-2030)
5.1.3 Global Nervous System Chemicals Sales Market Share by Application (2019-2030)
5.2 Global Nervous System Chemicals Revenue by Application (2019-2030)
5.2.1 Global Nervous System Chemicals Revenue by Application (2019-2024)
5.2.2 Global Nervous System Chemicals Revenue by Application (2025-2030)
5.2.3 Global Nervous System Chemicals Revenue Market Share by Application (2019-2030)
5.3 Global Nervous System Chemicals Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Nervous System Chemicals Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ely Lilly Nervous System Chemicals Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis(Teva Pharmaceuticals)
6.3.1 Actavis(Teva Pharmaceuticals) Corporation Information
6.3.2 Actavis(Teva Pharmaceuticals) Description and Business Overview
6.3.3 Actavis(Teva Pharmaceuticals) Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Actavis(Teva Pharmaceuticals) Nervous System Chemicals Product Portfolio
6.3.5 Actavis(Teva Pharmaceuticals) Recent Developments/Updates
6.4 Mylan(Viatris)
6.4.1 Mylan(Viatris) Corporation Information
6.4.2 Mylan(Viatris) Description and Business Overview
6.4.3 Mylan(Viatris) Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan(Viatris) Nervous System Chemicals Product Portfolio
6.4.5 Mylan(Viatris) Recent Developments/Updates
6.5 UCB
6.5.1 UCB Corporation Information
6.5.2 UCB Description and Business Overview
6.5.3 UCB Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.5.4 UCB Nervous System Chemicals Product Portfolio
6.5.5 UCB Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Intellipharmaceutics Nervous System Chemicals Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Astrazeneca Nervous System Chemicals Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lundbeck Nervous System Chemicals Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan(AbbVie)
6.9.1 Allergan(AbbVie) Corporation Information
6.9.2 Allergan(AbbVie) Description and Business Overview
6.9.3 Allergan(AbbVie) Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Allergan(AbbVie) Nervous System Chemicals Product Portfolio
6.9.5 Allergan(AbbVie) Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GSK Nervous System Chemicals Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Nervous System Chemicals Description and Business Overview
6.11.3 Otsuka Pharmaceutical Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Otsuka Pharmaceutical Nervous System Chemicals Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Nervous System Chemicals Description and Business Overview
6.12.3 Takeda Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Takeda Nervous System Chemicals Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 Novartis
6.13.1 Novartis Corporation Information
6.13.2 Novartis Nervous System Chemicals Description and Business Overview
6.13.3 Novartis Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Novartis Nervous System Chemicals Product Portfolio
6.13.5 Novartis Recent Developments/Updates
6.14 Johnson & Johnson
6.14.1 Johnson & Johnson Corporation Information
6.14.2 Johnson & Johnson Nervous System Chemicals Description and Business Overview
6.14.3 Johnson & Johnson Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Johnson & Johnson Nervous System Chemicals Product Portfolio
6.14.5 Johnson & Johnson Recent Developments/Updates
6.15 Eisai
6.15.1 Eisai Corporation Information
6.15.2 Eisai Nervous System Chemicals Description and Business Overview
6.15.3 Eisai Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Eisai Nervous System Chemicals Product Portfolio
6.15.5 Eisai Recent Developments/Updates
6.16 Kelun Pharmaceutical
6.16.1 Kelun Pharmaceutical Corporation Information
6.16.2 Kelun Pharmaceutical Nervous System Chemicals Description and Business Overview
6.16.3 Kelun Pharmaceutical Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Kelun Pharmaceutical Nervous System Chemicals Product Portfolio
6.16.5 Kelun Pharmaceutical Recent Developments/Updates
6.17 Humanwell Pharmaceutical
6.17.1 Humanwell Pharmaceutical Corporation Information
6.17.2 Humanwell Pharmaceutical Nervous System Chemicals Description and Business Overview
6.17.3 Humanwell Pharmaceutical Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Humanwell Pharmaceutical Nervous System Chemicals Product Portfolio
6.17.5 Humanwell Pharmaceutical Recent Developments/Updates
6.18 Enhua Pharmaceutical
6.18.1 Enhua Pharmaceutical Corporation Information
6.18.2 Enhua Pharmaceutical Nervous System Chemicals Description and Business Overview
6.18.3 Enhua Pharmaceutical Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Enhua Pharmaceutical Nervous System Chemicals Product Portfolio
6.18.5 Enhua Pharmaceutical Recent Developments/Updates
6.19 Yangzijiang Pharmaceutical
6.19.1 Yangzijiang Pharmaceutical Corporation Information
6.19.2 Yangzijiang Pharmaceutical Nervous System Chemicals Description and Business Overview
6.19.3 Yangzijiang Pharmaceutical Nervous System Chemicals Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Yangzijiang Pharmaceutical Nervous System Chemicals Product Portfolio
6.19.5 Yangzijiang Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nervous System Chemicals Industry Chain Analysis
7.2 Nervous System Chemicals Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nervous System Chemicals Production Mode & Process
7.4 Nervous System Chemicals Sales and Marketing
7.4.1 Nervous System Chemicals Sales Channels
7.4.2 Nervous System Chemicals Distributors
7.5 Nervous System Chemicals Customers
8 Nervous System Chemicals Market Dynamics
8.1 Nervous System Chemicals Industry Trends
8.2 Nervous System Chemicals Market Drivers
8.3 Nervous System Chemicals Market Challenges
8.4 Nervous System Chemicals Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Ely Lilly
Actavis(Teva Pharmaceuticals)
Mylan(Viatris)
UCB
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan(AbbVie)
GSK
Otsuka Pharmaceutical
Takeda
Novartis
Johnson & Johnson
Eisai
Kelun Pharmaceutical
Humanwell Pharmaceutical
Enhua Pharmaceutical
Yangzijiang Pharmaceutical
听
听
*If Applicable.